In this study, we aim to comprehensively characterize the research trajectory of PD-1/PD-L1 in RCC by integrating bibliometric data from 2005 to 2024 and over a decade of global clinical trial records. This evidence concerns the gene CD274 and renal cell adenocarcinoma.